[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.
September 12, 2023. # Download our press release (english version) # Télécharger...
More[Press Release] XENOTHERA strengthens its management team and governance. June 8, 2023.
June 8, 2023. # Download our press release (english version) # Télécharger...
More[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.
May 30, 2023. # Download our press release (english version) # Télécharger...
More[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.
April 5,2023. # Télécharger notre communiqué de presse (version française)
More[Press Release] The French biotech XENOTHERA, on a mission with business France in China
April 3, 2023. # Download our press release (english version) # Télécharger...
More[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1
January 05,2023. # Download our press release (english version)
More[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.
December 16,2022. # Download our press release (english version) # Télécharger notre...
More[Press Release] XENOTHERA signs a memorandum of understanding with the Vietnamese conglomerate Vingroup
September 9,2021. # Download our press release (english version) # Télécharger notre...
More[Press Release] 20 M€ raised by XENOTHERA to accelerate its development
June 29, 2021. # Download our press release (english version) # Télécharger...
More